中文
About Us
GV-971
Scientific Research Information
News
Social Responsibility
Careers
Contact Us
CN
Press Releases

Novel Drug Treatment Shows Improved Cognition in a Phase 3 Clinical Trial in Persons with Mild-to-Mo

GV-971 Gets Included in China National Reimbursement Drug List

GV-971 Global Phase III Clinical Trial Completes First Patient Dosed in Greater China

Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids
All
All
2022
2021
2020
2019
2018
2017
2015
05-13
2022
2022-05-13
Announcement on Early Termination of GV-971 Global Multi-Center Phase III Clinical Trial
01-13
2022
2022-01-13
Green Valley Obtains IND Approval from U.S. FDA for Sodium Oligomannate’s Global Phase II Clinical Trial in Treating Parkinson’s Disease
12-06
2021
2021-12-06
GV-971 Gets Included in China National Reimbursement Drug List
08-03
2021
2021-08-03
GV-971 Global Phase III Clinical Trial Completes First Patient Dosed in Greater China
06-16
2021
2021-06-16
GV-971 Global Phase III Clinical Trial Officially Initiates in Greater China
02-08
2021
2021-02-08
GV-971 Global Phase III Clinical Trial Completes First Patient Dosed Globally
11-06
2020
2020-11-06
GV-971 Global Multi-center Phase III Clinical Trial Kicks-off Patient Enrollment Process
07-17
2020
2020-07-17
Green Valley Site Kicks Off Construction on Carbohydrate Drug Manufacturing Facility in Shanghai